» Articles » PMID: 24532105

Evaluation of Factor V G1691A, Prothrombin G20210A, Factor XIII V34L, MTHFR A1298C, MTHFR C677T and PAI-1 4G/5G Genotype Frequencies of Patients Subjected to Cardiovascular Disease (CVD) Panel in South-east Region of Turkey

Overview
Journal Mol Biol Rep
Specialty Molecular Biology
Date 2014 Feb 18
PMID 24532105
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiovascular disease (CVD) risk factors, such as arterial hypertension, obesity, dyslipidemia or diabetes mellitus, as well as CVDs, including myocardial infarction, coronary artery disease or stroke, are the most prevalent diseases and account for the major causes of death worldwide. In the present study, 4,709 unrelated patients subjected to CVD panel in south-east part of Turkey between the years 2010 and 2013 were enrolled and DNA was isolated from the blood samples of these patients. Mutation analyses were conducted using the real-time polymerase chain reaction method to screen six common mutations (Factor V G1691A, PT G20210A, Factor XIII V34L, MTHFR A1298C and C677T and PAI-1 -675 4G/5G) found in CVD panel. The prevalence of these mutations were 0.57, 0.25, 2.61, 13.78, 9.34 and 24.27 % in homozygous form, respectively. Similarly, the mutation percent of them in heterozygous form were 7.43, 3.44, 24.91, 44.94, 41.09 and 45.66%, respectively. No mutation was detected in 92 (1.95%) patients in total. Because of the fact that this is the first study to screen six common mutations in CVD panel in south-east region of Turkey, it has a considerable value on the diagnosis and treatment of these diseases. Upon the results of the present and previous studied a careful examination for these genetic variants should be carried out in thrombophilia screening programs, particularly in Turkish population.

Citing Articles

Biochemical Association of MTHFR C677T Polymorphism with Myocardial Infarction in the Presence of Diabetes Mellitus as a Risk Factor.

Mallhi T, Shahid M, Rehman K, Khan Y, Alanazi A, Alotaibi N Metabolites. 2023; 13(2).

PMID: 36837870 PMC: 9958922. DOI: 10.3390/metabo13020251.


Methylenetetrahydrofolate reductase and psychiatric diseases.

Wan L, Li Y, Zhang Z, Sun Z, He Y, Li R Transl Psychiatry. 2018; 8(1):242.

PMID: 30397195 PMC: 6218441. DOI: 10.1038/s41398-018-0276-6.


Rivaroxaban attenuates thrombosis by targeting the NF-κB signaling pathway in a rat model of deep venous thrombus.

Ma J, Li X, Wang Y, Yang Z, Luo J Int J Mol Med. 2017; 40(6):1869-1880.

PMID: 29039441 PMC: 5716436. DOI: 10.3892/ijmm.2017.3166.


Genetic risk factors in patients with deep venous thrombosis, a retrospective case control study on Iranian population.

Hosseini S, Kalantar E, Hosseini M, Tabibian S, Shamsizadeh M, Dorgalaleh A Thromb J. 2015; 13:35.

PMID: 26557789 PMC: 4640381. DOI: 10.1186/s12959-015-0064-y.

References
1.
Ridker P, Miletich J, Hennekens C, Buring J . Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997; 277(16):1305-7. View

2.
Goyette P, Sumner J, Milos R, Duncan A, Rosenblatt D, Matthews R . Human methylenetetrahydrofolate reductase: isolation of cDNA mapping and mutation identification. Nat Genet. 1994; 7(4):551. View

3.
Kim K, Kim K, Kim B, Joo N, Cho D, Lee D . Relationship of plasminogen activator inhibitor 1 gene 4G/5G polymorphisms to hypertension in Korean women. Chin Med J (Engl). 2012; 125(7):1249-53. View

4.
Akar N, Akar E, Dalgin G, Sozuoz A, Omurlu K, Cin S . Frequency of Factor V (1691 G --> A) mutation in Turkish population. Thromb Haemost. 1998; 78(6):1527-8. View

5.
Thomas P, Fenech M . Methylenetetrahydrofolate reductase, common polymorphisms, and relation to disease. Vitam Horm. 2008; 79:375-92. DOI: 10.1016/S0083-6729(08)00413-5. View